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Abstract. 
Since 2010, the World Health Organization has been recommending that all suspected cases of malaria be 
confirmed with parasite-based diagnosis before treatment. These guidelines represent a paradigm shift away 
from presumptive antimalarial treatment of fever. Malaria rapid diagnostic tests (mRDTs) are central to 
implementing this policy, intended to target artemisinin-based combination therapies (ACT) to patients with 
confirmed malaria and to improve management of patients with nonmalarial fevers. The ACT Consortium 
conducted ten linked studies, eight in sub-Saharan Africa and two in Afghanistan, to evaluate the impact of 
mRDT introduction on case management across settings that vary in malaria endemicity and healthcare provider 
type. This synthesis includes 562,368 outpatient encounters (study size range 2,400–432,513). mRDTs were 
associated with significantly lower ACT prescription (range 8–69% versus 20–100%). Prescribing did not 
always adhere to malaria test results; in several settings, ACTs were prescribed to more than 30% of test-
negative patients or to fewer than 80% of test-positive patients. Either an antimalarial or an antibiotic was 
prescribed for more than 75% of patients across most settings; lower antimalarial prescription for malaria test-
negative patients was partly offset by higher antibiotic prescription. Symptomatic management with antipyretics 
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alone was prescribed for fewer than 25% of patients across all scenarios. In community health worker and 
private retailer settings, mRDTs increased referral of patients to other providers. This synthesis provides an 
overview of shifts in case management that may be expected with mRDT introduction and highlights areas of 
focus to improve design and implementation of future case management programs. 
INTRODUCTION 
Providing appropriate antimalarial treatment to patients who have malaria has been a 
long-standing challenge in fever case management and has traditionally relied on 
presumptive symptom-based diagnosis. Many people with malaria do not receive effective 
antimalarial medications, increasing their risk of severe disease or death. At the same time, 
many of those who receive antimalarials do not have malaria and are suffering from a 
nonmalaria illness which may need alternative treatment.1 To improve rational the use of 
artemisinin-based combination therapies (ACTs), the World Health Organization (WHO) 
recommended in 2010 that all suspected cases of malaria should have parasitological 
confirmation before treatment.2,3 These changes represent a paradigm shift from presumptive 
antimalarial treatment of fever to targeted use of ACTs only for those with a positive malaria 
test. 
Central to implementing this policy change is malaria rapid diagnostic tests (mRDTs), 
relatively simple, inexpensive, and reliable point-of-care tests that can be used where high-
quality microscopy services are not available.4 mRDTs are intended to improve the 
management of suspected malaria cases, increasing the use of first-line antimalarials in 
patients with confirmed malaria and encouraging the diagnosis and appropriate treatment of 
patients without malaria.1 After the WHO policy change, mRDT procurement has surged 
from 45 million tests globally in 2008 to 314 million in 2014.5 Parasite-based diagnosis 
before treatment is now a policy in public health facilities in most malaria-endemic countries, 
and mRDTs are also being introduced among private retail and community health 
providers.6–14 
Clinical trials and early pilot projects before the widespread adoption of mRDTs 
supported their use though with some heterogeneity of results.15 Compared with presumptive 
treatment with antimalarials, case management based on mRDTs generally reduced 
antimalarial prescription, particularly in settings with relatively high provider adherence to 
test results and low malaria prevalence.16–22 On the other hand, although provider adherence 
to negative mRDT results was high in some studies,16,17,23,24 it was low in others.25–27 
Comparable data from good-quality studies in a variety of contexts are needed to anticipate 
the effects of mRDT implementation as these tests are rolled out at scale. 
The ACT Consortium is a research partnership created to address key questions and 
inform policy on ACT delivery.28 The Consortium conducted studies in 10 countries in Africa 
and Asia, including 10 studies specifically designed to address questions on improving the 
targeting of ACTs through the use of mRDTs. These studies looked at the impact of mRDT 
introduction on fever case management across a range of clinical and epidemiological 
contexts and among various types of healthcare providers. Studies evaluated different mRDT 
intervention packages, leading to heterogeneity that precludes formal meta-analysis. The 
current synthesis compares individual study results to identify patterns across contexts and 
provide an overview of what may be expected from mRDT implementation programs. 
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METHODS 
Studies included in the analysis. 
ACT Consortium studies were included in this analysis if they collected data on patient 
consultations for suspected malaria, evaluated an intervention to implement mRDTs by 
healthcare providers, and included a comparison group without the mRDT intervention. The 
10 studies meeting these criteria are described in Table 1, including the abbreviation for each 
study used throughout the text. All studies received ethical approval from their host academic 
institutions and national authorities; see open-access publications for further details29–37 
(Leslie, T. et al., unpublished data). Data are available at the ACT Consortium data repository 
(https://actc.lshtm.ac.uk/) or from the authors on request. 
Eight studies took place in sub-Saharan Africa and two in Afghanistan, in a mix of rural 
and urban settings. mRDTs were introduced in health facilities only (Afgh1, Cam1, Ghan1, 
Tanz1, Tanz2, and Uga1), among community health workers (Afgh2 and Uga2), in private 
drug shops only (Uga3), or in a combination of public facilities, private pharmacies, and drug 
shops (Nige1). Seven studies were cluster-randomized trials of interventions to introduce 
mRDTs, two studies were individually randomized trials (Afgh1 and Ghan1), and one study 
was a descriptive “before and after” evaluation (Tanz1). All patients that were eligible in 
each study were included in the present analysis; typically, these were patients with suspected 
malaria, although one study included only children under age 5 years (Uga2), and two studies 
collected data on all patient consultations (Tanz2 and Uga1). Data were collected using 
provider-completed records of treatments administered (Afgh1, Afgh2, Ghan1, Uga1, and 
Uga2), patient exit interviews (Tanz1), both of these methods (Cam1, Nige1, and Tanz2), or 
provider-completed records with follow-up interviews of a subsample of patients (Uga3). 
From each study, “settings” and “scenarios” were identified for this analysis. Six studies 
were conducted in multiple settings (indicated by suffix a, b, and c), such as distinct 
geographical areas and malaria transmission zones (Afgh1, Afgh2, Cam1, Tanz1, and Uga2), 
or where providers used different methods of routine malaria diagnosis (presumptive care or 
microscopy; Afgh1 and Ghan1). Trial arms or comparison groups within a setting were 
termed scenarios. All settings included at least one scenario without mRDT interventions, and 
settings in three studies (Cam1, Nige1, and Tanz2) included multiple mRDT intervention 
scenarios. In total, the 10 studies were conducted in 18 settings, with 18 scenarios without 
mRDT interventions and 24 scenarios with mRDT interventions. 
Data were collected concurrently from scenarios with and without mRDT interventions in 
seven studies. In three studies (Nige1, Tanz1, and Tanz2), data from scenarios without 
mRDT interventions were collected before mRDT introduction. The scale of the interventions 
and their evaluations varied: for example, in Uga1 the intervention was implemented in 10 
health facilities, and data were collected on 432,513 patient encounters in the study area 
whereas Tanz1 evaluated a nationwide intervention, and data were collected from 3,456 
patients. 
Microscopy was widely available in all settings in Cam1 and available at some higher-
level facilities in Tanz1, particularly in the Tanz1/c scenario without mRDT interventions. 
The two individually randomized studies (Afgh1 and Ghan1) took place both in settings 
where microscopy was the standard practice and in settings where malaria diagnosis was 
symptom based. Microscopy services were nonexistent or very limited in the other six studies 
(Afgh2, Nige1, Tanz2, Uga1, Uga2, and Uga3). 
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Indicators of interest. 
To examine the impact of mRDTs on patient care, malaria testing and prescribing 
indicators were reviewed. Because the objective was to compare case management in areas 
with and without mRDT interventions, our first indicator of interest was the proportion of 
patients tested by the provider with any parasite-based diagnostic test (microscopy or 
mRDT). Prescribing indicators were the proportions of patients prescribed one or more of the 
following medicines: ACTs, non-ACT antimalarials, antibiotics (antibacterials), antifungals, 
antihelminthics, and antipyretics. The proportion of patients referred to another healthcare 
provider was also reviewed. 
The ACT indicator was adjusted to account for malaria epidemiology and differences in 
first-line antimalarial in two cases: In Afghanistan, Plasmodium vivax was treated with 
chloroquine and Plasmodium falciparum with ACT; in these settings, the proportion of 
patients prescribed any antimalarial is reported instead of ACT. In Nige1, prescription of 
sulfadoxine-pyrimethamine (SP) and ACTs are reported for the scenario without mRDT 
interventions, whereas only ACTs are reported for the scenarios with mRDT interventions. 
This reflects a change in treatment between the 2009 scenario without mRDT interventions 
(when ACTs were recommended but not yet widely used) and the 2011 scenarios with mRDT 
interventions (when ACTs had largely replaced SP). 
Analytical approach. 
Descriptive statistics on the indicators of interest were calculated from each scenario. 
Estimates for each indicator were made for scenarios without mRDTs and those with 
mRDTs. Prescribing indicators were further stratified by result of the diagnostic test 
performed by the healthcare provider. Odds ratios and 95% confidence intervals for 
indicators of interest within each setting were calculated using logistic regression with robust 
standard errors to account for clustering by the primary unit of sampling or randomization 
(see Supplemental Tables). Formal meta-analysis was deemed inappropriate because of the 
heterogeneity of interventions evaluated and study contexts. However, to aid comparisons 
between scenarios with and without mRDTs, the indicators of interest are presented as 
graphic point estimates by study arm. The analysis was conducted in STATA 14 (STATA 
Corp LP, College Station, TX). Factors which may explain variations in mRDT use are 
examined with additional qualitative data sources elsewhere.38 
RESULTS 
Proportion of patients tested. 
More patients were tested in scenarios where mRDTs had been introduced (Figure 1 and 
Supplemental Tables 1–3). However, even with mRDTs available, the percentage of patients 
tested varied widely, with 50% or fewer patients tested in five settings (Nige1, Tanz1/a, 
Tanz1/b, Tanz2, and Uga1), and nearly 100% in others (Afgh2/a, Afgh2/b, Uga/2, Uga2/b, 
and Uga3). The largest increases in proportion of patients tested were seen where mRDTs 
were introduced outside of health facilities (Afgh2, Uga2, and Uga3). Similar proportions of 
children and adults were tested in most scenarios, but in Nige1, Tanz1/a, and Uga1 test 
uptake was slightly higher for young children than for older patients. The proportion of 
patients tested is not reported in Afgh1 or Ghan1, where patients were individually 
randomized to mRDTs or microscopy (Afgh1/a, Afg1/b, and Ghan1/a), and to mRDTs or 
symptom-based diagnosis (Afgh1/c and Ghan1/b). 
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Patients were also tested with microscopy in Cam1 and, to a lesser extent, in Tanz1. In 
Cam1/a and Cam1/b, microscopy was common in all scenarios, and test use was not higher in 
scenarios with mRDT interventions. In scenarios without mRDT interventions, 80% of 
patients were tested with microscopy. In the four scenarios with mRDT interventions, 27–
61% of patients were tested with microscopy and 17–52% with mRDT (71–81% tested 
overall). Of the three Tanz1 settings, microscopy was most frequently used in the Tanz1/c 
scenario without mRDT interventions, where 29% of patients were tested with microscopy 
and 2% with mRDT; in the corresponding scenario with mRDT interventions, 8% were tested 
with microscopy and 63% with mRDT. 
Prescription of ACTs and other antimalarial medications. 
Overall, mRDTs were associated with lower ACT prescribing (Figure 2A and 
Supplemental Table 4). In 10/13 African settings, mRDT scenarios had statistically 
significantly lower ACT prescriptions than scenarios without mRDT interventions. In two 
African settings, there was little difference between mRDT and non-mRDT scenarios: Uga1, 
a high-transmission area where a high proportion of patients required ACTs even after testing 
and Ghan1/a, where all non-mRDT patients were randomized to testing with microscopy. In 
Nige1, where levels of testing were very low, presumptive diagnosis of malaria was common 
even where mRDTs were available. Prescription of ACT or SP in the scenario without mRDT 
interventions was similar to prescription of ACT in the three mRDT intervention scenarios 
(around 50%). In 4/5 Afghanistan settings, prescription of any antimalarial was much lower 
in scenarios with mRDT interventions than without; the exception was Afgh1/b, where 
(similar to Ghan1/a) all non-mRDT patients were randomized to testing with microscopy and 
where malaria transmission was low. 
Recorded prescription of non-ACT antimalarials (e.g., SP, quinine, oral, and artemisinin 
monotherapies) was generally uncommon, except in Afghanistan. In 11/13 African settings, 
non-ACTs were prescribed for fewer than 10% of patients both with and without mRDT 
interventions (data not shown). Prescription of non-ACT antimalarials was higher in Cam1/b 
(20.9% in the scenario without an mRDT intervention and approximately 15% in the two 
scenarios with mRDT interventions) and in Nige1 (52.8% in the scenario without an mRDT 
intervention and approximately 30% in the three scenarios with mRDT interventions). 
Overall, the finding of lower ACT prescription in scenarios with mRDT interventions was 
mostly due to malaria test-negative patients not receiving ACTs (Figure 2B–D and 
Supplemental Table 5). Fewer than 30% of test-negative patients were treated with ACTs in 
most mRDT intervention scenarios; exceptions were Cam1/a and Cam1/b, and Ghan1/a and 
Ghan1/b, where ACTs were prescribed for 39.2–49.1% of patients with negative malaria test 
results. There was no evident difference in this indicator by test type; in the Cam1/a and 
Cam1/b scenarios with mRDT interventions, ACTs were prescribed to 17.3–42.9% of 
microscopy test-negative patients and 15.6–45.9% of mRDT test-negative patients (data not 
shown). The percentages of malaria test-positive patients in scenarios with mRDT 
interventions who were prescribed ACTs ranged from 60.2% to 98.0% in 12/15 settings with 
data for this indicator. Prescription of ACTs to test-positive patients was over 90% in six of 
these settings, but was just 60.2–81.2% in another six settings, with 69.4–96.2% prescribed 
any antimalarial. In Tanz1/a, where stock-outs of ACTs in public health facilities were a 
major problem, ACT prescribing for test-positive patients was 18.2%. In Afgh1/a and 
Afgh2/a, 99.5% and 82.7% of test-positive patients were prescribed any antimalarial. 
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Prescription of antibiotics. 
In contrast to reduced ACT prescribing, the mRDT interventions were associated with 
significantly more prescribing of systemic antibiotic (antibacterial) medications in seven 
settings (Afgh1/c, Afgh2/a, Tanz1/a, Tanz1/b, Tanz1/c, Tanz2, and Uga3) (Figure 3 and 
Supplemental Tables 6–7). In scenarios with mRDT interventions, antibiotic prescribing 
patterns varied by mRDT result. In all settings except Nige1, 40.0–79.9% of patients who 
tested negative for malaria were prescribed antibiotics. Antibiotic prescription was similar in 
patients who were not tested. Among those with a positive malaria test result, fewer than 45% 
were prescribed antibiotics, with higher proportions in Cam1/a and Cam1/b. Prescription of 
both an antimalarial and a systemic antibiotic (Figure 4A and Supplemental Table 8) was 
relatively uncommon in all settings (< 25% of patients, except in Cam1 and Afgh2/b) and 
was similar or lower in scenarios with mRDT interventions. By contrast, the prescription of 
either an antimalarial or an antibiotic medicine was high in all settings (more than 68%, 
except in Tanz1/a) and similar or lower in scenarios with mRDT interventions (Figure 4B and 
Supplemental Table 9). Further details of antibiotic prescribing in ACT Consortium studies 
are presented elsewhere.39 
Prescription of other medicines. 
Data were recorded on prescription of other anti-infectives in some study settings. 
Prescription of systemic antifungals (fluconazole and griseofulvin) was reported in five 
settings (Cam1/a, Cam1/b, Ghan1/a, Ghan1/b, and Uga1); the proportion of patients 
prescribed these medicines across these settings was 2.6% or less (Supplemental Table 10). 
Prescription of antihelminthics (albendazole and mebendazole) was recorded in 13 settings 
(all study settings except those in Afgh2, Tanz2, and Uga2); the proportion of patients 
prescribed these medicines ranged from 0.3% to 33.3%, which did not appear attributable to 
whether the scenarios had an mRDT intervention or not (Supplemental Table 10). 
Prescription of antipyretic medicines alone, for symptomatic relief, without an 
antimalarial or an antibiotic, ranged from 0.3% to 23.7% across all scenarios and was similar 
or higher with mRDT interventions except in Nige1 (Figure 4C and Supplemental Table 11). 
Polypharmacy, defined as the prescription of three or more medicines, varied widely across 
settings (Figure 4D). However, in most settings, polypharmacy was comparable with and 
without mRDT interventions, but was significantly lower with mRDT interventions in four 
settings (Afgh1/b, Afgh2/a, Afgh2/b, and Cam2/b (Figure 4D and Supplemental Table 12). 
Referral. 
Figure 5 and Supplemental Table 13 show the percentage of patients referred to another 
care provider or facility. Referral was generally low across study settings. However, referral 
was significantly higher with mRDT interventions among community health workers, 
particularly in Uga2/a, Uga2/b, and Afgh2/b, and to a lesser extent in Uga3. Referral was 
uncommon (< 5%) across all scenarios in studies in public health facilities. 
DISCUSSION 
Providing appropriate treatment to patients who present with malaria-like symptoms 
remains a challenge in many endemic regions. This synthesis of data from 10 ACT 
Consortium studies illustrates the impact of mRDTs on case management. The data represent 
24 scenarios where mRDTs were introduced, compared with 18 scenarios without mRDT 
interventions. This synthesis found that mRDT interventions reduced prescription of first-line 
antimalarials across almost all settings, except where the tests were not often used. However, 
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prescribing did not always reflect test results: across a range of scenarios, ACTs were 
prescribed for some mRDT-negative cases, and at least as concerning, ACTs were not 
prescribed for all mRDT-positive cases. The use of mRDTs also influenced other treatment 
decisions, notably resulting in an increase of antibiotic prescription especially for test-
negative cases. Referral of patients to other healthcare providers was low across nearly all 
settings, with a few specific exceptions discussed below. 
What lessons can be learned from this synthesis, to inform expectations of programs that 
implement mRDTs at scale? Although mRDTs generally improve malaria case management, 
alone, they are not a panacea to solve the major challenge of effective fever management. 
Simply providing mRDTs is insufficient if health workers continue prescribing antimalarials 
to test-negative patients27,40 or if alternative treatments are not appropriate. The ACT 
Consortium studies evaluated a range of tailored and pretested elements as part of mRDT 
intervention strategies, such as enhanced provider training or community awareness 
activities.41,42 Anecdotally, interventions designed with more intensive formative research led 
to greater reductions in ACT prescription for test-negative patients; but such prescribing 
remained inappropriately high (10–49%). 
Furthermore, in five of the eight African studies included in this analysis, more than 20% 
of patients who tested positive for malaria at the point of care were not prescribed ACTs. 
Undertreatment of malaria in settings where mRDTs have been implemented has been 
recognized in a small proportion of cases (less than 5%), with few exceptions.43–45 However, 
results of this synthesis suggest that undertreatment may be a more common problem than 
previously recognized. The six settings with high ACT prescription for test-positive patients 
varied in terms of malaria epidemiology, geography, and provider type; the same is true for 
the six settings with lower ACT prescription for test-positive patients. To date, research into 
the reasons for this phenomenon has been limited, although ACT Consortium study results 
presented elsewhere suggest that provider motivations, stability of ACT supplies and 
preexisting antimalarial preferences account for some of this underprescription.38 Missed or 
ineffective treatment of malaria presents a risk to patients; a balance between reducing 
unnecessary antimalarial use while ensuring ACTs are provided to all malaria-positive cases 
needs to be integrated in future research, training, and implementation programs. 
This synthesis highlights the fact that effecting change in one healthcare practice can have 
knock-on consequences for other practices. In many ACT Consortium studies, mRDT 
implementation was associated with a higher level of antibiotic prescription, particularly for 
malaria test-negative patients.39 The proportion of patients prescribed either an antimalarial or 
an antibiotic was high, for more than 75% of cases across most settings, and this was 
approximately similar in settings with and without mRDT interventions. This suggests that in 
the absence of other diagnostic options, presumptive antimalarial treatment may be 
exchanged for presumptive antibiotic treatment when mRDTs are introduced. Many patients 
with uncomplicated febrile illness are likely to improve with symptomatic management only 
(e.g., antipyretic), as noted in WHO case management guidelines46,47; this approach was 
prescribed for just 0–24% of patients in ACT Consortium studies. Inappropriate use of 
antimicrobials is of increasing global concern because of rising resistance, which can result in 
longer illnesses, higher mortality, and increased treatment costs.48,49 A more comprehensive 
approach to case management is needed, rather than focusing on only a single diagnosis and 
medication (e.g., malaria mRDTs and ACTs), if unintended consequences are to be 
avoided.50 
Our data support the observation that introducing mRDTs may increase patient referral to 
other healthcare providers, particularly among community health workers and private 
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retailers.10,51 In particular, when a malaria test is negative, alternative diagnoses must be 
considered; the clinical skills and diagnostic capacity to achieve this are limited among 
providers with less formal training, so that, referral may be necessary for adequate case 
management. Overall, referral remained infrequent in ACT Consortium studies. Even when 
referral is recommended, patients are not always inclined or able to follow the 
recommendation.52–54 If current recommendations to scale up mRDTs in community and 
private healthcare settings are implemented, to improve referral practices in a way that is safe 
for individual patients, and without unduly burdening other parts of the healthcare system, the 
role of mRDTs will need to be better integrated into local pathways of treatment seeking and 
care provision.55–57 
The observed shifts in case management practices have cost implications for health 
systems and for patients. When mRDTs lead to reductions in ACT use, there can be 
substantial savings in ACT costs. However, additional costs are incurred for mRDT 
implementation: the tests themselves, alternative treatments provided to mRDT-negative 
patients, additional referrals, and the activities required for mRDT introduction, such as 
training, supervision, communication campaigns, and quality control. The overall cost impact 
in a given context will depend on several parameters, including the relative cost of ACTs and 
mRDTs, the amount of subsidy for each, the proportion of patients tested, the proportion who 
test positive, and provider adherence to test results. Analyses of the incremental economic 
cost per fever case managed have been published for four studies included in this synthesis. 
Where mRDTs were compared with microscopy (Afgh1, Ghan1, and Cam1), mRDTs were 
cost saving or costs were similar in Afghanistan,58 with an incremental provider cost per 
fever case managed ranging from 0.20 to 1.11 USD in in Ghana59 and Cameroon60 (2011 
USD). Where mRDTs were compared with clinical diagnosis, the incremental provider cost 
per fever case managed ranged from 0.24 to 10.9 USD across different transmission levels 
and provider types in Afghanistan, Ghana, and Uganda (2011 USD).58,59,61 These incremental 
costs may be considered good value for money if they lead to sufficient improvements in 
health outcomes. A full consideration of cost effectiveness would require costs from both 
health sector and household perspectives, extrapolation to final health outcomes such as cost 
per death or disability adjusted life year averted, and sensitivity analyses to explore the 
impact of variation in prescribing and referral practices. Ideally, a full analysis should also 
include the impact of malaria testing on enhancing malaria surveillance systems and resulting 
improvements in targeting of malaria interventions. 
The present analysis was subject to several limitations. Data were collected concurrently 
from scenarios with and without mRDT interventions in seven studies, whereas in the other 
three (Nige1, Tanz1, and Tanz2) data were collected before and after mRDT introduction 
(Table 1). In Nige1, the interval between the two data collection points corresponded with a 
shift in antimalarial use from SP to ACT; whereas ACT prescription decreased, any 
antimalarial prescription remained high ( 75%). In addition, some indicators varied in 
availability and precise definition across studies (see footnotes to Figures and Supplemental 
Tables). For example, in Uga2, prescription of antibiotics and polypharmacy was not reported 
because community health workers were only permitted to dispense antimalarials and 
antipyretics. In Tanz1, data on medicines prescribed were not available from scenarios 
without mRDTs, so data on medicines dispensed were used for all Tanz1 scenarios. In 
designing the ACT Consortium studies and mRDT implementation packages, investigators 
sought to accommodate varied and transitioning contexts while still obtaining data that could 
be compared across studies. This synthesis therefore did not aim to provide combined 
estimates of the size of effect of the impact of mRDTs (meta-analysis). Instead, comparison 
of findings from the individual studies identified clear patterns across diverse geographical, 
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epidemiological, and health sector contexts, indicating both robustness and generalizability of 
the results. 
In summary, evidence from ten ACT Consortium studies demonstrates that mRDT 
introduction can reduce prescription of ACTs. However, mRDTs are not an easy 
technological fix. Critically, challenges exist in ensuring that all patients who test positive for 
falciparum malaria are prescribed ACT; anything less endangers individual patients and the 
credibility of programs. It is also necessary to ensure that patients who test negative receive 
appropriate management, which may or may not include other antimicrobials. ACT 
Consortium studies were conducted between 2007 and 2013, and since that time, mRDT 
implementation programs continue to evolve. These combined results provide an overview of 
the generally positive shifts in case management that may be expected with mRDT 
introduction, and highlight issues that warrant particular attention in future work on point-of-
care diagnosis and fever and malaria case management. 
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FIGURE 1. Patients in scenarios without and with malaria rapid diagnostic test (mRDT) interventions that were 
tested with any malaria diagnostic test at the provider of (A) all patients, (B) patients under age five years, and 
(C) patients ages five years and older. Afgh1 and Ghan1 studies individually randomized patients to malaria 
diagnostic method and are not included in this analysis. Some settings had more than one mRDT intervention 
scenario, which are graphed separately using the color and symbol for the setting. These include Cam1/a and 
Cam1/b (two intervention scenarios each), Nige1 (three intervention scenarios), and Tanz2 (three intervention 
scenarios). See Table 1. Scenarios with denominators fewer than 50 patients in Figure 2B are Afgh2/a without 
mRDT interventions and Afgh2/b both with and without mRDT interventions. 
FIGURE 2. Patients prescribed an artemisinin-based combination therapy (ACT) of all patients in scenarios 
without and with malaria rapid diagnostic test (mRDT) interventions and by test result for all patients in 
scenarios with mRDT interventions. Graphs depict the percentage of patients prescribed ACT except for: Afgh1 
and Afgh2, where all antimalarials are included to account for Plasmodium vivax treatment; and Nige1 without 
mRDT interventions only, where ACT or sulfadoxine-pyrimethamine (SP) are included to reflect treatment 
practices at the time of data collection. Scenarios with denominators fewer than 10 patients are not graphed, 
resulting in some points without adjoining lines: Afgh2/a and Afgh2/b in the “Not tested” column and Afgh1/b, 
Afgh1/c, and Afgh2/b in the “Positive test result” column. Afgh1 and Ghan1 studies individually randomized 
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patients to malaria diagnostic method; data are not included in “Not tested” column because all patients in 
mRDT intervention scenarios were tested. Some settings had more than one mRDT intervention scenario, which 
are graphed separately using the color and symbol for the setting. These include Cam1/a and Cam1/b (two 
intervention scenarios each), Nige1 (three intervention scenarios), and Tanz2 (three intervention scenarios). See 
Table 1. The following scenarios with denominators fewer than 50 patients are included: Uga2 in the “Not 
tested” column, and Cam1/a (R1), Tanz1/b, and Uga2/a in the “Positive test result” column. All other scenarios 
had larger denominators. 
FIGURE 3. Patients prescribed an antibacterial of all patients in scenarios without and with malaria rapid 
diagnostic test (mRDT) interventions and by test result for all patients in scenarios with mRDT interventions. 
Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and 
symbol for the setting. These include Cam1/a and Cam1/b (two intervention scenarios each), Nige1 (three 
intervention scenarios), and Tanz2 (three intervention scenarios). See Table 1. Community health workers in 
Uga2 were not permitted to prescribe antibacterials medications, so this study is not included in figure 3. Afgh1 
and Ghan1 studies individually randomized patients to malaria diagnostic method; data are not included in (D) 
because all patients in scenarios with mRDT interventions were tested. Scenarios with denominators fewer than 
10 patients are not graphed, resulting in some points without adjoining lines: Afgh2/a and Afgh2/b in the “Not 
tested” column, and Afgh1/b, Afgh1/c, and Afgh2/b in the “Positive test result” column. The following 
scenarios with denominators fewer than 50 patients are included: Cam1/a (R1) and Tanz1/b in the “Positive test 
result” column. All other scenarios had larger denominators. 
FIGURE 4. Patients in scenarios without and with malaria rapid diagnostic test (mRDT) interventions prescribed 
(A) an antimalarial and an antibacterial, (B) an antimalarial or an antibacterial, (C) an antipyretic without an 
antimalarial or an antibacterial, and (D) three or more medicines. Some settings had more than one mRDT 
intervention scenario, which are graphed separately using the color and symbol for the setting. These include 
Cam1/a and Cam1/b (two intervention scenarios each); Nige1 (three intervention scenarios) and Tanz2 (three 
intervention scenarios). See Table 1. Community health workers in Uga2 were not permitted to prescribe 
antibacterials medications, so this study is not included in figure 4. Tanz2 did not record data on all medications 
prescribed, so this study is not included in (D). 
FIGURE 5. Patients in scenarios without and with malaria rapid diagnostic test (mRDT) interventions that were 
referred to another care provider or health facility. Ghan1, Tanz1, Tanz2, and Uga1 did not record data on 
referral. Case management was performed by community health workers in Afgh2 and Uga2, private drug store 
retailers in Uga3, and both public and private health facilities in Nige1. All other studies were conducted in 
public health facilities. 
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TABLE 1 
Description of studies included in the analysis 
Study country 
(reference) 
Context Healthcare 
provider type 
Dates Design Setting* Scenario 
description† 
Number of 
patients 
Number of 
clusters‡ 
C 2,005 12 Afgh1/a 
R1 2,048 12, same as C 
C 517 5 Afgh1/b 
R1 527 5, same as C 
C 323 5 
Afgh1 
Afghanistan 
(29) 
Urban and 
rural 
Public health 
facilities 
September 2009–
September 2010 
Individually 
randomized trial 
Afgh1/c 
R1 329 5, same as C 
C 607 6 Afgh2/a 
R1 733 6 
C 594 5 
Afgh2 
Afghanistan 
(Leslie T, under 
review) 
Urban and 
rural 
Community 
health workers 
October 2011–
May 2012 
Cluster-randomized 
trial 
Afgh2/b 
R1 466 5 
C 400 5 
R1 699 8 
Cam1/a 
R2 778 9 
C 281 4 
R1 932 10 
Cam1 
Cameroon (30) 
Urban and 
rural 
Public and 
mission health 
facilities 
October–
December 2011 
Cluster-randomized 
trial 
Cam1/b 
R2 891 10 
C 1,907 1 Ghan1/a 
R1 1,904 1, same as C 
C 1,727 3 
Ghan1 Ghana 
(31) 
Rural Public health 
facilities 
August 2007–
December 2008 
Individually 
randomized trial 
Ghan1/b 
R1 1,725 3, same as C 
C 1,642 100 
R1 1,588 41 
R2 1,850 47 
Nige1 Nigeria 
(32) 
Urban and 
rural 
Public health 
facilities and 
private 
medicine 
retailers 
July–December 
2009 (formative), 
June–December 
2011 (trial) 
Formative study 
followed by cluster-
randomized trial 
Nige1 
R3§ 1,508 41 
C 689 39 Tanz1/a 
R1 750 60 
C 559 56 Tanz1/b 
R1 388 60 
C 498 44 
Tanz1 Tanzania 
(33) 
Rural/periu
rban 
Public health 
facilities 
May–October 
2010 (baseline), 
April–July 2012 
(follow-up) 
Descriptive before 
and after evaluation
Tanz1/c 
R1 572 57 
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C 16,068 36 
R1 14,217 12 
R2 15,931 12 
Tanz2 Tanzania 
(34) 
Rural Public health 
facilities 
September 2010– 
January 2011 
(baseline), 
February 2011–
Mar. 2012 (trial)
Baseline, followed 
by cluster-
randomized trial 
Tanz2 
R3|| 13,973 12 
C 210,758 10 Uga1 Uganda 
(35) 
Rural Public health 
facilities 
April 2011–March 
2013 
Cluster-randomized 
trial 
Uga1 
R1 221,755 1 
C 2,444 32 Uga2/a 
R1 1,207 32 
C 10,625 31 
Uga2 Uganda 
(36) 
Rural Community 
health workers 
January–
December 2011 
Cluster-randomized 
trial 
Uga2/b 
R1 7,872 30 
C 8,109 10 Uga3 Uganda 
(37) 
Rural Private 
medicine 
retailers 
January–
December 2011 
Cluster-randomized 
trial 
Uga3 
R2 10,365 10 
Further details of the studies are available from individual study publications. 
* Some studies had multiple “settings,” defined as distinct geographical areas, malaria transmission zones, or different standard practices of malaria diagnosis. Where the 
study had only one setting, the study and setting abbreviations are the same. 
† C = Without malaria rapid diagnostic test (mRDT) interventions; R1 = mRDT intervention with basic provider training; R2 = mRDT intervention with enhanced provider 
training; R3 = mRDT intervention with enhanced provider training and other activities. 
‡ Clusters were health facilities in all studies, except Nige1 (health facilities and private medicine retailers), Uga2 (villages) and Uga3 (drug shops within a single 
administrative area, and drug shops in a neighboring administrative area if the distance between drug shops was < 1 km). 
§ The R3 intervention in Nige1 also included school-based activities. 
|| The R3 intervention in Tanz2 also included patient sensitization. 
 Page 18 of 39 
SUPPLEMENTAL TABLE 1 
Patients tested by any malaria diagnostic test 
Study (by 
setting) 
Without mRDT 
interventions percentage 
numerator/denominator 
With mRDT 
interventions percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
Afgh1/a* NA NA NA 
Afgh1/b* NA NA NA 
Afgh1/c* NA NA NA 
0 98.8 Afgh2/a 
0/607 724/733 
† 
0 100 Afgh2/b 
0/594 466/466 
† 
78.3 (1): 70.7 (1): 0.67 
313/400 494/699 (0.17, 2.66) 
– (2): 79.5 (2): 1.08 
Cam1/a‡ 
– 617/776 (0.28, 4.1) 
80.4 (1): 81.0 (1): 1.04 
226/281 757/933 (0.23, 4.7) 
– (2): 77.8 (2): 0.85 
Cam1/b3 
– 692/889 (0.15, 4.7) 
Ghan1/a* NA NA NA 
Ghan1/b* NA NA NA 
1.7 (1): 29.9 (1): 25.5 
472/1,576 (7.5, 86) 
(2): 23.2 (2): 18.0 
428/1,844 (5.0, 64) 
(3): 15.8 (3): 11.2 
Nige1§ 
27/1,634 
237/1,502 (3.08, 40) 
7.3 48.4 12.0 Tanz1/a 
50/689 363.750 (4.2, 34.6) 
12.7 43.1 5.2 Tanz1/b 
71/559 167/387 (2.26, 12.0) 
31.3 71.5 5.5 Tanz1/c 
156/498 409/572 (2.30, 13.2) 
0 (1): 39.1 
5,556/14,216 
(2): 39.7 
6,332/15,931 
(3): 40.6 
Tanz2|| 
0/16,068 
5,673/13,972 
† 
7.3 52.9 14.4 Uga1 
15,285/210,758 117,350/221,755 (6.1, 33.9) 
0 96.0 Uga2/a 
0/10,625 1,150/1,198 
† 
0 98.7 Uga2/b 
0/2,444 7,736/7,840 
† 
0 97.3 Uga3 
0/8,109 10,078/10,357 
† 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included 
in this analysis. 
† Odds ratio undefined; approaches infinity. 
‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
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§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
|| Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced 
training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
SUPPLEMENTAL TABLE 2 
Patients under age 5 years tested by any malaria diagnostic test 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
Afgh1/a* NA NA NA 
Afgh1/b* NA NA NA 
Afgh1/c* NA NA NA 
0.0 100.0 Afgh2/a 
0/47 76/76 
† 
0.0 100.0 Afgh2/b 
0/20 15/15 
† 
85.2 (1): 64.4 (1): 0.32 
116/680 (0.04, 2.42) 
(2): 81.2 (2): 0.75 
Cam1/a‡ 
109/128 
190/234 (0.12, 4.7) 
85.2 (1): 84.0 (1): 0.91 
352/419 (0.18, 4.7) 
(2): 77.4 (2): 0.60 
Cam1/b‡ 
92/108 
291/376 (0.09, 3.85) 
Ghan1/a* NA NA NA 
Ghan1/b* NA NA NA 
2.0 (1): 32.8 (1): 23.8 
38/116 (5.46, 103) 
(2): 30.9 (2): 21.9 
43/139 (4.96, 96.5) 
(3): 27.7 (3): 18.7 
Nige1§ 
6/299 
38/137 (3.27, 107) 
3.5 50.4 28.4 Tanz1/a 
14/405 259/514 (7.9, 102) 
10.7 40.5 5.7 Tanz1/b 
33/308 100/247 (2.41, 13.3) 
32.2 72.2 5.48 Tanz1/c 
103/320 268/371 (2.16, 13.9) 
0.0 (1): 37.7 † 
0/6,559 1,981/5,270 – 
– (2): 38.5 – 
– 2,346/6,101 – 
– (3): 39.1 – 
Tanz2|| 
– 1,820/4,649 – 
8.9 61.0 16.0 Uga1 
5,774/64,825 40,978/67,159 (6.1, 42) 
0.0 96.0 Uga2/a 
0/2,444 1,150/1,198 
† 
0.0 98.7 Uga2/b 
0/10,625 7,736/1,198 
† 
0.0 98.3 Uga3 
0/2,761 3,829/3,895 
† 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
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* Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included 
in this analysis. 
† Odds ratio undefined; approaches infinity. 
‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
|| Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced 
training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
SUPPLEMENTAL TABLE 3 
Patients ages 5 years and older tested by any malaria diagnostic test 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
Afgh1/a* NA NA NA 
Afgh1/b* NA NA NA 
Afgh1/c* NA NA NA 
0.0 98.6 Afgh2/a 
0/558 633/642 
† 
0.0 100.0 Afgh2/b 
0/573 449/449 
† 
75.0 (1): 72.8 (1): 0.89 
204/272 378/519 (0.28, 2.90) 
– (2): 78.8 (2): 1.24 
Cam1/a‡ 
– 427/542 (0.37, 4.1) 
77.5 (1): 78.6 (1): 1.07 
134/173 403/513 (0.24, 4.7) 
– (2): 78.2 (2): 1.04 
Cam1/b3 
– 401/513 (0.20, 5.5) 
Ghan1/a* NA NA NA 
Ghan1/b* NA NA NA 
1.5 (1): 29.5 (1): 26.9 
20/1,306 424/1,438 (7.3, 99) 
– (2): 22.3 (2): 18.5 
– 375/1,679 (4.8, 71) 
– (3): 14.3 (3): 10.7 
Nige1§ 
– 191/1,336 (2.85, 40) 
12.7 44.1 5.4 Tanz1/a 
36/284 104/236 (1.77, 16.6) 
15.1 47.9 5.1 Tanz1/b 
38/251 67/140 (1.92, 13.8) 
29.8 70.1 5.5 Tanz1/c 
53/178 141/201 (2.21, 13.9) 
0.0 (1): 40.0 † 
0/9,429 3,572/8,926 – 
– (2): 40.6 – 
– 3,975/9,787 – 
– (3): 41.4 – 
Tanz2|| 
– 3,849/9,301 – 
6.5 49.9 14.4 Uga1 
9,298/143,834 74,313/148,980 (6.23, 33.3) 
Uga2/a NA NA NA 
Uga2/b NA NA NA 
 Page 21 of 39 
0.0 96.7 Uga3 
0/5,625 6,156/6,369 
† 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included 
in this analysis. 
† Odds ratio undefined; approaches infinity. 
‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
|| Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced 
training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
SUPPLEMENTAL TABLE 4 
Patients prescribed ACT 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
42.0 36.1 0.78 Afgh1/a 
843/2,005 740/2,048 (0.68, 0.90) 
24.4 20.1 0.78 Afgh1/b 
126/517 106/527 (0.54, 1.13) 
87.6 34.7 0.07 Afgh1/c 
283/323 114/329 (0.02, 0.25) 
77.9 26.6 0.10 Afgh2/a 
471/605 188/708 (0.04, 0.25) 
95.9 0.6 0.00 Afgh2/b 
567/591 3/463 (0.00, 0.00) 
79.5 (1): 43.5 (1): 0.20 
314/395 294/676 (0.06, 0.61) 
– (2): 37.9 (2): 0.16 
Cam1/a* 
– 286/754 (0.05, 0.52) 
69.8 (1): 55.1 (1): 0.53 
194/278 496/900 (0.28, 1.02) 
– (2): 46.5 (2): 0.38 
Cam1/b2 
– 408/877 (0.17, 0.84) 
63.7 62.3 0.94 Ghan1/a 
1,210/1,900 1,180/1,893 (0.83, 1.08) 
91.6 69.0 0.20 Ghan1/b 
1,577/1,722 1,188/1,721 (0.07, 0.62) 
56.9 (1): 49.3 (1): 0.74 
934/1,642 717/1,453 (0.40, 1.35) 
– (2): 45.4 (2): 0.63 
– 828/1,823 (0.38, 1.03) 
– (3): 54.2 (3): 0.90 
Nige1* 
– 808/1,409 (0.51, 1.57) 
20.1 8.5 0.37 Tanz1/a† 
138/688 64/750 (0.17, 0.79) 
49.2 25.5 0.35 Tanz1/b† 
275/559 99/388 (0.20, 0.61) 
57.0 35.1 0.41 Tanz1/c† 
284/498 201/572 (0.24, 0.68) 
Tanz2‡ 43.6 (1): 15.8 (1): 0.24 
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7,008/16,068 2,246/14,217 (0.15, 0.40) 
– (2): 11.6 (2): 0.17 
– 1,846/15,931 (0.10, 0.28) 
– (3): 9.5 (3): 0.14 
– 1,329/13,973 (0.08, 0.22) 
53.8 50.8 0.89 Uga1 
113,411/210,758 112,673/221,755 (0.67, 1.19) 
95.1 8.2 0.00 Uga2/a 
2,310/2,428 94/1,149 (0.00, 0.01) 
99.2 45.7 0.01 Uga2/b 
10,500/10,589 3,512/7,677 (0.00, 0.01) 
99.1 60.0 0.01 Uga3 
7,981/8,055 5,933/9,987 (0.01, 0.04) 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. Table presents the 
percentage of patients prescribed artemisinin-based combination therapy (ACT) except for: Afgh1 and Afgh2, 
where the percentage prescribed all antimalarials is presented to account for Plasmodium vivax treatment; and 
Nige1 without mRDT interventions only, where ACT or sulfadoxine-pyrimethamine (SP) is presented to reflect 
treatment practices at the time of data collection. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
‡ ACTs obtained by patient at the consultation (ACTs prescribed not available). 
§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
SUPPLEMENTAL TABLE 5 
Patients in scenarios with mRDT interventions prescribed ACT, by malaria test result and not tested 
 Percentage patients prescribed an ACT (95% CI) numerator/denominator 
Study (by 
setting) 
Positive test result Negative test result Not tested 
99.5 (97.9, 99.9) 12.6 (5.1, 27.7) Afgh1/a*†‡ 
552/555 188/1,493 
NA 
19.2 (1.7, 76.0) Afgh1/b*†‡ – 
100/521 
NA 
34.5 (8.4, 75.1) Afgh1/c*†‡ – 
113/328 
NA 
82.7 (63.3, 93.0) 4.0 (1.7, 9.2) Afgh2/a*‡ 
163/197 20/503 
– 
0.4 (0.1, 1.3) Afgh2/b*‡ – 
2/459 
– 
(1): 70.2 (37.3, 90.3) (1): 39.2 (13.4, 72.8) (1): 45.2 (28.7, 62.7) 
33/47 167/426 89/197 
(2): 79.6 (62.1, 90.3) (2): 24.6 (7.4, 57.2) (2): 35.3 (6.1, 82.0) 
Cam1/a§ 
117/147 110/447 54/153 
(1): 72.4 (58.2, 83.1) (1): 42.5 (29.3, 56.9) (1): 48.5 (40.5, 56.6) 
254/351 157/369 81/167 
(2): 70.1 (54.6, 82.0) (2): 18.3 (8.8, 34.2) (2): 51.6 (28.6, 73.9) 
Cam1/b§ 
246/351 57/312 99/192 
98.2 (96.7, 99.0) 45.9 (43.2, 48.6) (1): 45.0 (29.1, 61.9) 
584/595 596/1,298 453/1,007 
– – (2): 48.2 (38.3, 58.2) 
– – 674/1,399 
– – (3): 56.9 (46.1, 67.1) 
Ghan1/a† 
– – 710/1,248 
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97.5 (88.0, 99.5) 49.1 (1.0, 98.9) Ghan1/b† 
692/710 496/1,011 
NA 
(1): 74.4 (68.3, 79.6) (1): 21.4 (10.3, 39.3) 
238/320 24/112 
(2): 66.9 (48.4, 81.3) (2): 21.6 (10.8, 38.5) 
95/142 59/273 
(3): 60.2 (40.3, 77.2) (3): 26.5 (11.3, 50.4) 
Nige1|| 
59/98 36/136 
NA 
18.2 (7.0, 39.7) 4.9 (2.5, 9.6) 9.3 (4.9, 17.1) Tanz1/a¶ 
14/77 14/283 36/387 
94.4 (56.6, 99.5) 13.4 (8.1, 21.4) 28.2 (18.3, 40.8) Tanz1/b¶ 
17/18 20/149 62/220 
68.2 (53.4, 80.1) 5.1 (1.9, 12.9) 36.2 (17.3, 60.7) Tanz1/c¶ 
131/192 11/217 59/163 
(1): 78.8 (64.6, 88.3) (1): 17.0 (10.7, 26.0) (1): 4.6 (2.2, 9.6) 
1,146/1,455 685/4,024 401/8,660 
(2): 80.2 (65.2, 89.8) (2): 4.2 (1.8, 9.7) (2): 3.0 (1.2, 7.0) 
1,361/1,696 191/4,541 286/9,599 
(3): 75.6 (50.3, 90.4) (3): 3.6 (1.6, 8.2) (3): 2.6 (1.2, 5.7) 
Tanz2# 
944/1,249 157/4,332 218/8,299 
93.2 (89.7, 95.5) 2.7 (2.1, 3.5) 34.2 (23.1, 47.3) Uga1 
75,808/81,359 977/35,711 35,717/104,405 
66.7 (41.7, 84.8) 3.1 (1.4, 6.4) 69.6 (48.7, 84.6) Uga2/a 
24/36 32/1,041 32/46 
98.0 (96.9, 98.7) 1.1 (0.6, 1.8) 93.1 (80.4, 97.8) Uga2/b 
3,318/3,385 43/4,067 95/102 
97.9 (96.5, 98.7) 1.2 (0.8, 1.9) 96.4 (91.4, 98.5) Uga3 
5,551/5,670 47/3,868 269/279 
ACT = artemisinin-based combination therapy; CI = confidence interval; mRDT = malaria rapid diagnostic 
tests; NA = not applicable. 
* Table presents the percentage of patients in scenarios with mRDT interventions prescribed ACT except for 
Afgh1 and Afgh2, where the percentage prescribed all antimalarials is presented to account for Plasmodium 
vivax treatment. 
† Patients in the Afgh1 and Ghan1 studies were individually randomized to malaria diagnostic method; data are 
not included in this analysis because all patients in scenarios with mRDT interventions were tested. 
‡ Data not included in the analysis when denominators were less than 10. 
§ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
|| Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced 
training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
¶ ACTs obtained by patient at the consultation; data on ACTs prescribed not available in Tanz1. 
# Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
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SUPPLEMENTAL TABLE 6 
Patients prescribed a systemic antibacterial 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
38.1 40.8 1.12 Afgh1/a 
763/2,005 836/2,048 (0.97, 1.03) 
73.3 78.9 1.36 Afgh1/b 
379/517 416/527 (0.76, 2.43) 
14.2 57.1 8.0 Afgh1/c 
46/323 188/329 (2.70, 23.9) 
18.2 54.1 5.3 Afgh2/a 
110/605 383/708 (2.28, 12.4) 
48.4 68.5 2.32 Afgh2/b 
286/591 317/463 (0.85, 6.3) 
72.8 (1): 78.5 (1): 1.36 
287/394 534/680 (0.68, 2.84) 
– (2): 78.5 (2): 1.36 
Cam1/a* 
– 595/757 (0.76, 2.43) 
50.4 (1): 56.9 (1): 1.30 
140/278 510/897 (0.48, 3.53) 
– (2): 47.3 (2): 0.89 
Cam1/b1 
– 415/877 (0.35, 2.27) 
30.8 32.1 1.06 Ghan1/a 
586/1,900 608/1,896 (0.92, 1.21) 
28.0 32.6 1.24 Ghan1/b 
483/1,723 560/1,719 (0.90, 1.72) 
23.2 (1): 13.6 (1): 0.52 
382/1,642 199/1,467 (0.29, 0.93) 
– (2): 18.2 (2): 0.73 
– 330/1,817 (0.46, 1.17) 
– (3): 15.1 (3): 0.59 
Nige1† 
– 223/1,474 (0.34, 1.03) 
29.7 44.7 1.92 Tanz1/a‡ 
204/688 335/749 (1.20, 3.08) 
35.2 56.4 2.38 Tanz1/b‡ 
197/688 219/388 (1.54, 3.68) 
33.1 49.0 1.94 Tanz1/c‡ 
165/498 280/572 (1.32, 3.83) 
61.5 (1): 73.2 (1): 1.71 
9,875/16,068 10,407/14,217 (1.25, 2.35) 
– (2): 75.4 (2): 1.92 
– 12,014/15,931 (1.42, 2.61) 
– (3): 70.5 (3): 1.50 
Tanz24§ 
– 9,853/13,973 (1.19, 1.89) 
53.7 57.9 1.18 Uga1 
113,102/210,758 128,406/221,755 (0.79, 1.77) 
Uga2/a|| NA NA NA 
Uga2/b|| NA NA NA 
19.4 34.9 2.24 Uga3 
48/248 87/249 (1.41, 3.54) 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
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† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
‡ Any antibacterials obtained by patients at the consultation; data on systemic antibacterials prescribed not 
available in Tanz1. 
§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is 
not included in this analysis. 
SUPPLEMENTAL TABLE 7 
Patients in scenarios with mRDT interventions prescribed a systemic antibacterial, by malaria test result and not 
tested 
Percentage prescribed an antibacterial (95% CI) numerator/denominator Study (by 
setting) Positive test result Negative test result Not tested 
3.6 (1.8, 7.1) 54.7 (37.9, 70.4) Aghg1/a* 
20/555 816/1,493 
NA 
70.7 (60.0, 91.1) Afgh1/b*† – 
415/521 
NA 
57.3 (23.0, 85.8) Afgh1/c*† – 
188/328 
NA 
8.1 (4.8, 13.5) 72.8 (49.9, 87.8) Afgh2/a† 
16/197 366/503 
– 
68.8 (41.9, 87.1) Afgh2/b† – 
316/459 
– 
(1): 66.0 (48.2, 80.1) (1): 79.9 (65.9, 89.1) (1): 80.0 (57.5, 92.2) 
31/47 341/427 160/200 
(2): 74.7 (65.3, 82.2) (2): 83.1 (75.4, 88.9) (2): 69.3 (64.6, 73.6) 
Cam1/a‡ 
109/146 375/451 106/153 
(1): 58.0 (42.4, 72.2) (1): 63.5 (46.9, 77.4) (1): 42.5 (25.2, 61.9) 
203/350 (2): 52.6 (45.1, 60.0) 71/167 
(2): 43.7 (31.7, 56.5) 164/312 (2): 47.9 (28.2, 68.3) 
Cam1/b‡ 
153/350 – 92/192 
14.6 (12.0, 17.7) 40.0 (37.4, 42.7) Ghan1/a* 
87/595 521/1,301 
NA 
18.0 (11.1, 27.9) 42.8 (12.4, 79.9) Ghan1/b* 
128/710 432/1,009 
NA 
(1): 17.5 (13.3, 22.7) (1): 26.1 (12.2, 47.4) (1): 11.1 (5.6, 20.9) 
55/314 29/111 114/1,026 
(2): 14.9 (8.5, 24.7) (2): 13.3 (6.7, 24.6) (2): 19.5 (14.9, 25.2) 
21/141 37/279 271/1,388 
(3): 20.2 (8.5, 41.0) (3): 21.6 (13.9, 32.2) (3): 13.9 (8.9, 21.3) 
Nige1§ 
20/99 29/134 172/1,233 
31.6 (17.3, 50.5) 53.0 (42.2, 63.6) 41.3 (30.4, 52.2) Tanz1/a|| 
24/76 150/283 160/387 
44.4 (11.4, 83.3) 58.4 (47.2, 68.8) 56.4 (44.7, 67.4) Tanz1/b|| 
8/18 87/149 124/220 
30.7 (20.8, 42.9) 61.8 (50.4, 71.9) 53.4 (39.4, 66.8) Tanz1/c|| 
59/192 134/217 87/163 
(1): 26.5 (13.4, 45.8) (1): 74.2 (67.1, 80.2) (1): 80.6 (75.5, 84.8) 
386/1,455 2,985/4,024 6,979/6,880 
(2): 36.1 (25.4, 48.3) (2): 77.7 (69.9, 83.9) (2): 81.3 (75.1, 86.2) 
612/1,696 3,527/4,541 7,800/9,599 
(3): 26.3 (18.0, 36.6) (3): 74.7 (69.2, 79.6) (3): 74.9 (68.6, 80.3) 
Tanz2¶ 
328/1,249 3,238/4,332 6,214/8,299 
40.5 (30.6, 51.2) 69.3 (65.3, 73,0) 66.3 (60.5, 71.7) Uga1 
32,935/81,359 24,737/35,711 69,178/104,405 
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Uga2/a# NA NA NA 
Uga2/b# NA NA NA 
23.6 (16.3, 33.0) 46.0 (37.7, 54.6) Uga3† 
30/127 52/113 
– 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Patients in the Afgh1 and Ghan1 studies were individually randomized to malaria diagnostic method; data are 
not included in this analysis because all patients in scenarios with mRDT interventions were tested. 
† Data not included in the analysis when denominators were less than 10. 
‡ Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
§ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
|| Any antibacterials obtained by patients at the consultation; data on systemic antibacterials prescribed not 
available in Tanz1. 
¶ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
# Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is 
not included in this analysis. 
SUPPLEMENTAL TABLE 8 
Patients prescribed an antimalarial and an antibacterial 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
1.2 1.5 Afgh1/a 
25/2,005 30/2,048 
1.18 (0.66, 2.11) 
10.6 8.7 Afgh1/b 
55/517 46/527 
0.80 (0.54, 1.19) 
4.6 4.3 Afgh1/c 
15/323 14/329 
0.91 (0.50, 1.68) 
47.4 0.2 Afgh2/a 
280/51 1/463 
0.00 (0.00, 0.02) 
16.7 3.1 Afgh2/b 
101/605 22/708 
0.16 (0.06, 0.40) 
66.1 (1): 37.7 
259/392 253/672 
(1): 0.31 (0.15, 
0.65) 
– (2): 32.8 
Cam1/a* 
– 247/753 
(2): 0.25 (0.10, 
0.61) 
43.9 (1): 40.1 
122/278 359/896 
(1): 0.85 (0.33, 
2.24) 
– (2): 28.1 
Cam2/b* 
– 247/875 
(2): 0.50 (0.19, 
1.31) 
12.3 12.4 Ghan1/a 
234/1,899 235/1,893 
1.01 (0.83, 1.22) 
23.8 15.3 Ghan1/b 
410/1,722 263/1,719 
0.58 (0.32, 1.04) 
14.7 (1): 12.3 
241/1,642 174/1,459 
(1): 0.81 (0.48, 
1.39) 
– (2): 14.0 
– 253/1,805 
(2): 0.95 (0.58, 
1.55) 
– (3): 11.9 
Nige1† 
– 175/1,472 
(3): 0.78 (0.51, 
1.21) 
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6.8 4.1 Tanz1/a‡ 
47/688 31/749 
0.59 (0.27, 1.28) 
18.2 12.9 Tanz1/b‡ 
102/559 50/388 
0.66 (0.36, 1.22) 
15.5 14.7 Tanz1/c‡ 
77/498 84/572 
0.94 (0.49, 1.82) 
24.2 (1): 6.9 
3,891/16,068 974/14,217 
(1): 0.23 (0.14, 
0.37) 
– (2): 5.7 
– 908/15,931 
(2): 0.19 (0.12, 
0.31) 
– (3): 3.6 
Tanz2§ 
– 500/13,973 
(3): 0.12 (0.07, 
0.19) 
23.8 23.5 Uga1 
50,098/210,758 52,212/221,755 
0.99 (0.59, 1.65) 
Uga2/a|| NA NA NA 
Uga2/b|| NA NA NA 
19.4 14.2 Uga3 
48/248 33/233 
0.69 (0.45, 1.06) 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
‡ Antimalarials and any antibacterials obtained by patients at the consultation; data on medicines prescribed not 
available in Tanz1. 
§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is 
not included in this analysis. 
SUPPLEMENTAL TABLE 9 
Patients prescribed an antimalarial or an antibacterial 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
78.9 75.5 Afgh1/a 
1,581/2,005 1,546/2,048 
0.83 (0.74, 0.93) 
87.0 90.3 Afgh1/b 
450/517 476/527 
1.39 (0.73, 2.66) 
97.2 87.5 0.20 Afgh1/c 
314/323 288/329 0.08, 0.48) 
97.0 68.9 Afgh2/a 
573/591 319/463 
0.07 (0.03, 0.19) 
79.3 77.5 Afgh2/b 
480/605 549/708 
0.90 (0.32, 2.56) 
94.2 (1): 92.5 
372/394 629/680 
(1): 0.73 (0.19, 
2.76) 
– (2): 90.9 
Cam1/a* 
– 687/757 
(2): 0.59 (0.16, 
2.14) 
97.1 (1): 88.1 
270/278 790/897 
(1): 0.22 (0.10, 
0.49) 
– (2): 79.8 
Cam1/b* 
– 700/877 
(2): 0.12 (0.05, 
0.27) 
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82.9 82.2 Ghan1/a 
1,575/1,899 1,557/1,894 
0.95 (0.80, 1.12) 
97.0 85.7 Ghan1/b 
1,670/1,722 1,501/1,719 
0.21 (0.10, 0.48) 
84.5 (1): 81.7 
1,369/1,642 1158/1,460 
(1): 0.82 (0.37, 
1.79) 
– (2): 80.4 
– 1,451/1,805 
(2): 0.75 (0.41, 
1.37) 
– (3): 86.8 
Nige1† 
– 1,278/1,473 
(3): 1.20 (0.49, 
2.93) 
46.2 52.7 Tanz1/a‡ 
318/688 395/749 
1.30 (0.81, 2.09) 
68.7 70.4 Tanz1/b‡ 
384/559 273/388 
1.08 (0.61, 1.93) 
79.1 72.2 Tanz1/c‡ 
394/498 413/572 
0.69 (0.40, 1.16) 
87.9 (1): 85.4 
14,125/16,068 12,146/14,217 
(1): 0.81 (0.61, 
1.08) 
– (2): 84.4 
– 13,446/15,931 
(2): 0.74 (0.55, 
1.01) 
– (3): 79.0 
Tanz2§ 
– 11,032/13,973 
(3): 0.52 (0.40, 
0.66) 
85.5 87.0 Uga1 
180,106/210,758 192,831/221,755 
1.13 (0.67, 1.91) 
Uga2/a|| NA NA NA 
Uga2/b|| NA NA NA 
100.0 78.7 Uga3 
248/248 188/239 
0.00¶ 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
‡ Antimalarials and any antibacterials obtained by patients at the consultation; data on medicines prescribed not 
available in Tanz1. 
§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is 
not included in this analysis. 
¶ Odds ratio undefined; approaches zero. 
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SUPPLEMENTAL TABLE 10 
Patients prescribed a systemic antihelminthic, and patients prescribed a systemic antifungal 
Antihelminthics Antifungals 
Without mRDT 
interventions 
With mRDT 
interventions 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Afgh1/a 0.5 (10/2,005) 0.3 (7/2,048) 0 (0/2,005) 0 (0/2,048) 
Afgh1/b 0.8 (4/517) 0.8 (4/527) 0 (0/517) 0 (0/527) 
Afgh1/c 0.0 (0/323) 0.3 (1/329) 0 (0/323) 0 (0/329) 
Afgh2/a* NA NA NA NA 
Afgh2/b* NA NA NA NA 
11.4 (45/394) (1): 4.3 (29/680) 0.8 (3/394) (1): 1.2 (8/680) 
– – 
Cam1/a† 
– 
(2): 8.5 (76/897) 
– 
(2): 1.9 (17/897) 
(1): 7.1 (54/757) (1): 0.4 (3/757) Cam1/b† 8.3 (23/278) 
(2): 10.4 (91/877) 
1.4(4/278) 
(2): 2.6 (23/877) 
Ghan1/a 31.6 (600/1,900) 33.3 (631/1,896) 0.6 (11/1,900) 0.7 (13/1,896) 
Ghan1/b 8.6 (149/1,723) 11.3 (195/1,719) 0.1 (1/1,723) 0.3 (6/1,719) 
(1): 0.3 (4/1,588) (1): 0 (0/1,588) 
(2): 0.3 (5/1,850) (2): 0 (0/1,850) 
Nige1‡ 2.0 (33/1,642) 
(3): 1.3 (19/1,508) 
0.1 (1/1642) 
(3): 0 (0/1,508) 
Tanz1/a§ 1.7 (12/688) 4.5 (34/749) 0 (0/688) 0 (0/749) 
Tanz1/b§ 3.2 (18/559) 7.2 (28/388) 0 (0/559) 0 (0/388) 
Tanz1/c§ 2.2 (11/498) 3.1 (18/572) 0 (0/498) 0 (0/572) 
(1) NA (1) NA 
(2) NA (3) NA 
Tanz2* NA 
(4) NA 
NA 
(2) NA 
Uga1 14.6 (30,865/210,758) 16.1 (35,683/221,755) 0.1 (195/210,758) 0.1 (318/221,755) 
Uga2/a* NA NA NA NA 
Uga2/b* NA NA NA NA 
Uga3 4.0 (10/248) 5.2 (13/249) 0 (0/248) 0 (0/249) 
 Page 30 of 39 
mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Data on systemic antihelminthics and antifungals prescribed were not collected from Afgh2, Tanz2, and Uga2. 
† Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training. 
‡ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training 
plus school-based activities. 
§ Systemic antihelminthics and antifungals obtained by patients at the consultation; data on medicines prescribed not available in Tanz1. 
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SUPPLEMENTAL TABLE 11 
Patients prescribed an antipyretic without an antimalarial or an antibiotic 
Without mRDT 
interventions 
With mRDT 
interventions 
Study (by 
setting) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
19.7 22.7 Afgh1/a 
395/2,005 464/2,048 
1.19 (1.07, 1.34) 
10.8 8.2 Afgh1/b 
56/517 43/527 
0.73 (0.35, 1.53) 
2.8 12.2 Afgh1/c 
9/323 40/329 
4.8 (2.16, 10.8) 
1.2 17.3 Afgh2/a 
7/591 80/463 
17.4 (3.41, 89) 
0.3 11.6 Afgh2/b 
2/605 82/708 
39.5 (12.9, 121) 
0.5 (1): 4.2 
2/392 28/671 
(1): 8.5 (1.34, 54) 
– (2): 7.1 
Cam1/a* 
– 53/749 
(2): 14.9 (2.44, 
90) 
1.8 (1): 3.7 
5/278 33/895 
(1): 2.09 (0.66. 
6.7) 
– (2): 5.8 
Cam1/b* 
– 51/874 
(2): 3.38 (1.01, 
11.4) 
12.6 14.3 Ghan1/a 
239/1,899 271/1,893 
1.16 (0.96, 1.40) 
2.4 10.2 Ghan1/b 
42/1,722 176/1,719 
4.6 (1.98, 10.5) 
7.6 (1): 3.1 
138/1,642 44/1,459 
(1): 0.39 (0.17, 
0.89) 
– (2): 8.9 
– 161/1,825 
(2): 1.19 (0.66, 
2.13) 
– (3): 3.9 
Nige1† 
– 58/1,489 
(3): 0.50 (0.18, 
1.39) 
23.7 18.8 Tanz1/a‡ 
163/688 141/749 
0.75 (0.46, 1.23) 
12.7 12.1 Tanz1/b‡ 
71/559 47/388 
0.95 (0.49, 1.83) 
9.4 18.2 Tanz1/c‡ 
47/498 104/572 
2.13 (1.25, 3.64) 
6.4 (1): 10.9 
(1,020/15,953) 1,545/14,217 
(1): 1.78 (1.32, 
2.41) 
– (2): 11.4 
– 1,818/15,931 
(2): 1.89 (1.34, 
2.65) 
– (3): 14.1 
Tanz2§ 
– 1,964/13,973 
(3): 2.39 (1.89, 
3.04) 
10.1 8.4 Uga1 
21,803/210,758 18,630/221,755 
0.79 (0.43, 1.45) 
Uga2/a|| NA NA NA 
Uga2/b|| NA NA NA 
0.0 14.6 Uga3 
0/248 34/233 
¶ 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
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† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
‡ Antipyretics obtained by patients at the consultation; data on medicines prescribed not available in Tanz1. 
§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is 
not included in this analysis. 
¶ Odds ratio undefined; approaches infinity. 
SUPPLEMENTAL TABLE 12 
Patients prescribed three or more medicines 
Without mRDT 
interventions 
With mRDT 
interventions Study 
(by 
settin
g) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
16.1 15.1 Afgh1/a 
322/2,005 309/2,048 
0.93 (0.80, 1.08) 
36.0 34.7 Afgh1/b 
186/517 183/527 
0.95 (0.85, 1.06) 
60.1 38.3 Afgh1/c 
194/323 126/329 
0.41 (0.19, 0.92) 
62.3 3.2 Afgh2/a 
368/591 15/463 
0.02 (0.01, 0.05) 
28.1 10.2 Afgh2/b 
170/605 72/708 
0.29 (0.10, 0.88) 
87.5 (1): 82.3 
350/400 575/699 
(1): 0.66 (0.28, 
1.58) 
– (2): 79.8 
Cam1/a* 
– 621/778 
(2): 0.57 (0.26, 
1.22) 
78.6 (1): 71.5 
221/281 667/933 
(1): 0.68 (0.33, 
1.41) 
– (2): 61.3 
Cam1/b* 
– 546/891 
(2): 0.43 (0.19, 
0.98) 
91.8 91.4 Ghan1/a 
(1,751/1,907) (1,740/1,904) 
0.95 (0.75, 1.19) 
Ghan1/b 90.3 (1,559/1,727) 88.2 (1,521/1,725) 0.80 (0.61, 1.07) 
60.8 (1): 56.4 
965/1,587 896/1,588 
(1): 0.83 (0.45, 
1.54) 
– (2): 53.2 
– 985/1,850 
(2): 0.73 (0.39, 
1.38) 
– (3): 57.1 
Nige1† 
– 861/1,508 
(3): 0.86 (0.51, 
1.44) 
13.8 18.6 Tanz1/a‡ 
95/688 139/748 
1.42 (0.80, 2.53) 
24.2 30.7 Tanz1/b‡ 
143/498 119/388 
1.39 (0.90, 2.14) 
28.7 26.6 Tanz1/c‡ 
143/498 152/571 
0.90 (0.52, 1.57) 
(1): NA (1): NA 
(2): NA (2): NA 
Tanz2§ NA 
(3): NA (3): NA 
50.9 52.2 Uga1 
107,348/210,758 115,850/221,755 
1.05 (0.66, 1.68) 
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Uga2/a|| NA NA NA 
Uga2/b|| NA NA NA 
54.0 60.2 Uga3 
134/248 150/249 
1.29 (0.80, 2.07) 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
† Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
‡ Medicines obtained by patients at the consultation; data on medicines prescribed not available in Tanz1. 
§ Tanz2 did not record data on all medications prescribed, so this study is not included in Figure 4D. 
|| Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is 
not included in this analysis. 
SUPPLEMENTAL TABLE 13 
Patients referred to another care provider or health facility 
Without mRDT 
interventions 
With mRDT 
interventions Study 
(by 
settin
g) 
Percentage 
numerator/denominator 
Percentage 
numerator/denominator 
Odds ratio (95% 
CI) 
0.1 0.0 Afgh1/a 
3/2,005 1/2,048 
0.33 (0.03, 3.47) 
0.0 0.0 Afgh1/b 
0/323 0/329 
– 
0.2 0.4 Afgh1/c 
1/517 2/527 
1.97 (0.13, 29.1) 
29.0 64.2 Afgh2/a 
172/594 299/466 
4.4 (2.28, 8.5) 
23.9 15.7 Afgh2/b 
145/607 115/732 
0.59 (0.19, 1.81) 
0.8 (1): 0.9 
3/399 6/695 
(1): 1.15 (0.28, 
4.7) 
– (2): 1.4 
Cam1* 
– 11/769 
(2): 1.92 (0.47, 
7.8) 
0.4 (1): 1.3 
1/280 12/903 
(1): 3.76 (0.70, 
20.1) 
– (2): 3.5 
Cam2* 
– 30/864 
(2): 10.0 (1.38, 
73) 
Ghan1/a† NA NA NA 
Ghan1/b† NA NA NA 
1.0 (1): 1.9 
17/1,630 30/1,548 
(1): 1.88 (0.59, 
5.9) 
– (2): 1.7 
– 31/1,833 
(2): 1.63 (0.61, 
4.4) 
– (3): 3.8 
Nige1‡ 
– 57/1,491 
(3): 3.77 (0.89, 
15.93) 
Tanz1/a† NA NA NA 
Tanz1/b† NA NA NA 
Tanz1/c† NA NA NA 
(1): NA (1): NA 
(2): NA (2): NA 
Tanz2†§ NA 
(3): NA (3): NA 
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Uga1† NA NA NA 
1.0 35.1 Uga2/b 
109/10,599 821/1,168 
52 (34.8, 77) 
13.1 70.3 Uga2/a 
314/2,404 2,706/77,16 
15.8 (9.3, 27) 
3.5 12.1 Uga3 
279/8,039 1,234/10,226 
3.82 (0.82, 17.8) 
CI = confidence interval; mRDT = malaria rapid diagnostic test; NA = not applicable. 
* Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs 
supplied with enhanced training. 
† Ghan1, Tanz1, Tanz2, and Uga1 did not record data on referral. 
‡ Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities. 
§ Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with 
enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization. 
FIGURE 1: Patients in scenarios without and with mRDT interventions that were tested with any malaria diagnostic test at the provider of (a) all 
patients, (b) patients under age five years, and (c) patients ages five years and older.1,2,3 
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1Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis. 
2Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and symbol for the setting. These include Cam1/a and Cam1/b 
(two intervention scenarios each); Nige1 (three intervention scenarios); and Tanz2 (three intervention scenarios). See Table 1. 
3Scenarios with denominators fewer than fifty patients in Figure 2b are Afgh2/a without mRDT interventions and Afgh2/b both with and without mRDT interventions. 
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FIGURE 2: Patients prescribed an ACT of all patients in scenarios without and with mRDT interventions, and by test result for all patients in 
scenarios with mRDT interventions. 1,2,3,4,5 
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1 Graphs depict the percentage of patients prescribed ACT except for: Afgh1 and Afgh2, where all antimalarials are included to account for P. vivax treatment; and Nige1 
without mRDT interventions only, where ACT or sulfadoxine-pyrimethamine (SP) are included to reflect treatment practices at the time of data collection. 
2Scenarios with denominators fewer than ten patients are not graphed, resulting in some points without adjoining lines: Afgh2/a and Afgh2/b in the “Not tested” column 
and Afgh1/b, Afgh1/c, and Afgh2/b in the “Positive test result” column. 
3Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method; data are not included in “Not tested” column since all patients in mRDT 
intervention scenarios were tested. 
4Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and symbol for the setting. These include Cam1/a and Cam1/b 
(two intervention scenarios each); Nige1 (three intervention scenarios); and Tanz2 (three intervention scenarios). See Table 1. 
5The following scenarios with denominators fewer than fifty patients are included: Uga2 in the “Not tested” column; and Cam1/a (R1), Tanz1/b, and Uga2/a in the “Positive 
test result” column. All other scenarios had larger denominators. 
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FIGURE 3: Patients prescribed an antibacterial of all patients in scenarios without and with mRDT interventions, and by test result for all patients 
in scenarios with mRDT interventions.1,2,3,4,5 
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1 Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and symbol for the setting. These include Cam1/a and Cam1/b 
(two intervention scenarios each); Nige1 (three intervention scenarios); and Tanz2 (three intervention scenarios). See Table 1. 
2Community health workers in Uga2 were not permitted to prescribe antibacterials medications, so this study is not included in Figure 3. 
3Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method; data are not included in Figure 3d since all patients in scenarios with mRDT 
interventions were tested. 
4Scenarios with denominators fewer than ten patients are not graphed, resulting in some points without adjoining lines: Afgh2/a and Afgh2/b in the “Not tested” column; 
and Afgh1/b, Afgh1/c, and Afgh2/b in the “Positive test result” column. 
5The following scenarios with denominators fewer than fifty patients are included:  Cam1/a (R1) and Tanz1/b in the “Positive test result” column. All other scenarios had 
larger denominators. 
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FIGURE 4: Patients in scenarios without and with mRDT interventions prescribed (a) an antimalarial and an antibacterial, 
(b) an antimalarial or an antibacterial (c) an antipyretic without an antimalarial or an antibacterial, and (d) three or more 
medicines.1,2,3 
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1Some settings had more than one mRDT intervention scenario, which are graphed separately using the color and symbol for the setting. 
These include Cam1/a and Cam1/b (two intervention scenarios each); Nige1 (three intervention scenarios); and Tanz2 (three intervention 
scenarios). See Table 1. 
2Community health workers in Uga2 were not permitted to prescribe antibacterials medications, so this study is not included in Figure 4. 
3Tanz2 did not record data on all medications prescribed, so this study is not included in Figure 4d. 
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FIGURE 5: Patients in scenarios without and with mRDT interventions that were referred to another care provider or 
health facility.1,2 
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1Ghan1, Tanz1, Tanz2, and Uga1 did not record data on referral. 
2Case management was performed by community health workers in Afgh2 and Uga2, private drug 
store retailers in Uga3, and both public and private health facilities in Nige1. All other studies were 
conducted in public health facilities. 
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